BACKGROUND: Metronidazole is one of the most commonly used antimicrobial agents for the treatment of Helicobacter pylori infection. Resistance to metronidazole has been reported worldwide but with a wide range of prevalence. We started using the classical triple therapy (bismuth, tetracycline, and metronidazole) for H. pylori infection in 1991 but recently have experienced a decline in its efficacy in curing the infection. Thus our aim was to investigate in a single center the prevalence of metronidazole-resistant H. pylori over a period of 5 years. MATERIALS AND METHODS: A total of 1,015 different H. pylori strains collected over a period of 5 years were tested for sensitivity against metronidazole, ampicillin, tetracycline, and imipenem. Antibiotic sensitivity was tested by the disk diffusion and agar dilution methods. To elucidate further the possible relationship between these metronidazole-resistant strains, genomic DNA digestion by the Hae III endonuclease and ribotyping were undertaken in a selected group of isolates. RESULTS: In 1991, 29 of 132 (22.0%) tested strains of H. pylori were found to be resistant to metronidazole. Since our initiation at that time of a triple therapy of bismuth, metronidazole, and tetracycline, the prevalence of metronidazole-resistant strains rose rapidly to 73.2% in 1995. All H. pylori isolates were sensitive to ampicillin, tetracycline, and imipenem. A high degree of genomic heterogeneity was found among these isolates. Thus it is unlikely that the resistant strains of H. pylori were originated from a single clone. CONCLUSIONS: This study shows a rapid increase in metronidazole-resistant H. pylori with the use of an anti-Helicobacter regimen that contains metronidazole. We anticipate that the efficacy of metronidazole-containing anti-Helicobacter regimens will decline with the rapid rise in resistant strains of H. pylori.
BACKGROUND:Metronidazole is one of the most commonly used antimicrobial agents for the treatment of Helicobacter pylori infection. Resistance to metronidazole has been reported worldwide but with a wide range of prevalence. We started using the classical triple therapy (bismuth, tetracycline, and metronidazole) for H. pyloriinfection in 1991 but recently have experienced a decline in its efficacy in curing the infection. Thus our aim was to investigate in a single center the prevalence of metronidazole-resistant H. pylori over a period of 5 years. MATERIALS AND METHODS: A total of 1,015 different H. pylori strains collected over a period of 5 years were tested for sensitivity against metronidazole, ampicillin, tetracycline, and imipenem. Antibiotic sensitivity was tested by the disk diffusion and agar dilution methods. To elucidate further the possible relationship between these metronidazole-resistant strains, genomic DNA digestion by the Hae III endonuclease and ribotyping were undertaken in a selected group of isolates. RESULTS: In 1991, 29 of 132 (22.0%) tested strains of H. pylori were found to be resistant to metronidazole. Since our initiation at that time of a triple therapy of bismuth, metronidazole, and tetracycline, the prevalence of metronidazole-resistant strains rose rapidly to 73.2% in 1995. All H. pylori isolates were sensitive to ampicillin, tetracycline, and imipenem. A high degree of genomic heterogeneity was found among these isolates. Thus it is unlikely that the resistant strains of H. pylori were originated from a single clone. CONCLUSIONS: This study shows a rapid increase in metronidazole-resistant H. pylori with the use of an anti-Helicobacter regimen that contains metronidazole. We anticipate that the efficacy of metronidazole-containing anti-Helicobacter regimens will decline with the rapid rise in resistant strains of H. pylori.
Authors: M Kato; Y Yamaoka; J J Kim; R Reddy; M Asaka; K Kashima; M S Osato; F A El-Zaatari; D Y Graham; D H Kwon Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191
Authors: L K Siu; W K Leung; A F Cheng; J Y Sung; T K Ling; J M Ling; E K Ng; J Y Lau; S C Chung Journal: J Clin Microbiol Date: 1998-10 Impact factor: 5.948
Authors: E J van der Wouden; A de Jong; J C Thijs; J H Kleibeuker; A A van Zwet Journal: Antimicrob Agents Chemother Date: 1999-06 Impact factor: 5.191
Authors: E J van der Wouden; A A van Zwet; G D Vosmaer; J A Oom; A de Jong; J H Kleibeuker Journal: Emerg Infect Dis Date: 1997 Jul-Sep Impact factor: 6.883